← Analysis page  ·  Goldman Sachs hub  ·  Research hub

Actionable insights — ServiceNow (NOW) 2Q26 preview

The repeatable analysis behind the call: not what the target is, but how a sell-side setup is read — written so the method can be rerun on the next software print.
2026-JUL-08 · Goldman Sachs Research — Americas Software (Borges, Hager) · note (PDF) ↗ · full analysis
How to read this page: each insight is a method — the diagnostic Goldman ran to size the setup and the multiple, and the signal to watch when re-running it on another name. The boxed line shows how it played out for ServiceNow this quarter.

1. Read the guide against trailing actuals — and price the conservatism in it

The repeatable method
  1. Put the forward guide next to the most recent actual for the same metric (here cRPO: 2Q guided ~17.25% organic vs 1Q actual ~20.0%) — the size of the implied deceleration is the real message, not the headline number.
  2. Ask why the guide stepped down. If the cut reflects added prudence after a one-off (Middle-East deal slippage, ~75bps hit to 1Q subscription growth) rather than eroding demand, the bar has been set low on purpose.
  3. Anchor the beat to history: compare the required beat to the multi-quarter average. A ~150bps cRPO beat matching the 3-year average, or a ~100bps subscription beat matching the prior 8 quarters, is a "normal" beat — not a stretch.
  4. Conclude on setup, not direction: a conservatively-set guide + an average-sized beat = a favorable print without needing a blowout.
Here: NOW guided 2Q organic cRPO to ~17.25% (vs ~20.0% 1Q) with Middle-East conservatism layered in, so Goldman's upside case (20.5–21.5% cRPO, 22–22.5% subscription) is just an average-magnitude beat against a lowered bar.
Watch for

2. Strip the acquired growth to judge the core

The repeatable method
  1. For any serial acquirer, decompose headline growth into organic vs. inorganic before comparing quarters — acquisitions inflate the reported number and mask the trend that actually re-rates the stock.
  2. Quantify each deal's contribution in basis points (here: Moveworks ~100bps, Armis ~125bps, Veza+Pyramid <50bps) and subtract to recover the organic line.
  3. Track the organic deceleration rate across years, not the level — management guiding ~200bps of core deceleration vs 300/300/200bps prior is the "stabilization" signal that carries the thesis.
  4. Treat M&A quality separately: distinguish gap-filling deals from position-of-weakness deals, and size tuck-ins (ai.work "in the tens of millions") so they don't distort the read.
Here: Goldman backs out ~225bps+ of acquired contribution from NOW's 19.5% headline cRPO guide to isolate ~17.25% organic, then judges the company's health on whether that organic line stabilizes.
Watch for

3. Name the single re-rating driver, then track its specific proof points

The repeatable method
  1. Reduce the multiple debate to one binary question the market is actually pricing (here: is ServiceNow relevant in the enterprise-AI stack, or disrupted by it?).
  2. Pre-commit to the concrete evidence that would answer it — Goldman names two: organic-revenue stabilization, and the analyst having to raise whole-company revenue estimates over time.
  3. Separate valuable growth from vanity growth: an AI-ACV target rising while total-revenue guidance is held forces the question of net-new budget vs. reallocation — weigh the composition (deeper workflow penetration, data gravity) not just the number.
  4. Let the driver flow to the multiple: the price-target cut here is a comps-driven de-rating (30x→27x), explicitly separated from the unchanged business call — so the re-rating catalyst is the proof points landing, not estimate tweaks.
Here: Goldman keeps Buy on NOW but cuts the target to $145 on lower comps, while pinning the re-rate to whether AI use cases (ITSM Level-1 automation, <100-day ROI, NVDA/FDX/CVS customers) convert into stabilizing organic revenue and upward WholeCo revisions.
Watch for

Methods distilled from a proprietary Goldman Sachs Global Investment Research note (PDF linked above), for personal study. Not investment advice. Source material © Goldman Sachs Global Investment Research.